{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000526","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2025-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.190650+00:00","generated_at":"2026-05-27T05:10:15.343173+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MaxCyte acquires SeQure Dx for $4.5M cash; adds gene-editing safety assessment services","bullets":["Initial consideration $4.5M in cash; up to $2.5M additional contingent on revenue targets.","SeQure reported ~$1.7M revenue and ~$6.5M loss (Jan–Nov 2024 unaudited); net assets $0.7M.","Acquisition expected to be accretive to MaxCyte's revenue growth; expands cell/gene therapy offerings.","SeQure specializes in on-target and off-target editing assessments for viral and non-viral modalities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000526","json":"https://secwatch.observer/filing/0001558370-25-000526.json","markdown":"https://secwatch.observer/filing/0001558370-25-000526.md","text":"https://secwatch.observer/filing/0001558370-25-000526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/0001558370-25-000526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/mxct-20250130x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T05:10:15.343173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}